文献速递糖尿病

COVID-19疫情期间1年内使用远程医疗改善儿童1型糖尿病CGM血糖指标并增加就诊次数

Improved CGM Glucometrics and More Visits for Pediatric Type 1 Diabetes Using Telemedicine During 1 Year of COVID-19.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

本研究评估了COVID-19疫情期间以虚拟照护为主的模式对儿童1型糖尿病(T1D)患者血糖指标的影响。纳入555例使用持续葡萄糖监测(CGM)的1-17岁T1D患者,比较疫情前后各约1年的数据。结果显示就诊频率从3.8次增至4.3次(P<0.001),92%为虚拟就诊;血糖管理指标(GMI)从7.9%略降至7.8%(P<0.001)。就诊频率未减少者GMI显著改善(8.0%降至7.8%,P<0.001),而就诊频率减少者无改善(P=0.86)。

要点

  • 疫情期间92%的就诊为虚拟远程医疗,就诊频率从3.8次增至4.3次(P<0.001)。
  • 总体GMI从7.9%略降至7.8%(P<0.001)。
  • 就诊频率未减少者GMI从8.0%降至7.8%(P<0.001),减少者无显著变化(P=0.86)。

核心结论

  • 疫情期间以远程医疗为主的照护模式使T1D儿童和青少年就诊频率总体增加,CGM血糖指标改善。
  • 需要进一步研究以了解儿科T1D成功使用远程医疗的相关因素。

研究设计与样本

  • 研究纳入1-17岁T1D患者,病程要求≥1年(≥6岁)或≥6个月(<6岁),且在疫情前(2019年4月1日至2020年3月15日)和疫情期间(2020年4月1日至2021年3月15日)均有至少1次就诊并记录CGM数据。
  • 数据从电子健康记录中提取,样本量为555例。

主要发现

  • 样本中46%为男性,87%为白人,79%使用胰岛素泵,平均年龄12.3±3.4岁,T1D病程5.9±3.5年,基线糖化血红蛋白A1c为8.0±1.0%(64±10.9 mmol/mol)。
  • 糖尿病就诊频率从疫情前的3.8±1.7次/期增加至疫情期间的4.3±2.2次/期(P<0.001),疫情期间92%的就诊为虚拟就诊。
  • 血糖管理指标(GMI)从疫情前的7.9%(63 mmol/mol)略降至疫情期间的7.8%(62 mmol/mol)(P<0.001)。
  • 就诊频率相等或增加者(n=437,占样本79%)GMI显著改善,从8.0%降至7.8%(64降至62 mmol/mol)(P<0.001)。
  • 就诊频率降低者GMI无显著变化(7.8% [62 mmol/mol],P=0.86)。

关键数值与推荐

  • 研究纳入标准:年龄1-17岁,T1D病程≥1年(≥6岁)或≥6个月(<6岁),疫情前后均有至少1次就诊并记录CGM数据。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究以了解与儿科T1D成功使用远程医疗相关的因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The COVID-19 pandemic led to rapid adoption of telemedicine for the care of youth with type 1 diabetes (T1D). We assessed the utility of a primarily virtual care model by comparing glucometrics from a pediatric sample with T1D using continuous glucose monitoring (CGM) both before and during the pandemic. METHODS: Pediatric patients aged 1 to 17 years with T1D duration ≥ 1 year if ≥ 6 years old or ≥ 6 months if < 6 years old, with ≥ 1 visit with recorded CGM data both prepandemic (April 1, 2019-March 15, 2020) and during the pandemic (April 1, 2020-March 15, 2021) were included. Data were extracted from the electronic health record. RESULTS: Our sample comprised 555 young people (46% male, 87% White, 79% pump-treated), mean age 12.3 ± 3.4 years, T1D duration 5.9 ± 3.5 years, baseline glycated hemoglobin A1c 8.0 ± 1.0% (64 ± 10.9 mmol/mol). Diabetes visit frequency increased from 3.8 ± 1.7 visits/prepandemic period to 4.3 ± 2.2 visits/pandemic period (P < 0.001); during pandemic period, 92% of visits were virtual. Glucose management indicator (GMI) improved slightly from 7.9% (63 mmol/mol) prepandemic to 7.8% (62 mmol/mol) during the pandemic (P < 0.001). Those with equal or greater visit frequency (n = 437 [79% of sample]) had significant improvement in GMI (8.0% to 7.8% [64 to 62 mmol/mol], P < 0.001), whereas those with lower visit frequency did not (7.8 [62 mmol/mol], P = 0.86). CONCLUSIONS: Children and adolescents with T1D using CGM before and during the pandemic showed an overall increase in visit frequency using primarily telemedicine-based care and improved CGM glucometrics. Further research is needed to understand factors associated with successful use of telemedicine for pediatric T1D.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kaushal T, Tinsley LJ, Volkening LK, et al. Improved CGM Glucometrics and More Visits for Pediatric Type 1 Diabetes Using Telemedicine During 1 Year of COVID-19. J Clin Endocrinol Metab. 2022. PMID: 35948357. doi:10.1210/clinem/dgac476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。